Schedule a Meeting
Download Brochure
Table of Content
Get a Price
February 2025
Principal Consultant
Reviewed By
The global monoclonal antibodies therapeutics market size is calculated at US$ 265.17 in 2024, grew to US$ 304.52 billion in 2025, and is projected to reach around US$ 1057.91 billion by 2034. The market is expanding at a CAGR of 14.84% between 2025 and 2034. Monoclonal is heavily used in various therapeutic areas, due to which the monoclonal antibodies therapeutics market is expected to grow exponentially in the coming years.
Over 30 targets and illnesses, most often cancer, have been approved for monoclonal antibody therapies. The pharmaceutical business, which traditionally depended on tiny compounds, now uses antibodies as its foundation. Monoclonal antibodies (mAbs) offer superior target selectivity than small compounds, which reduces toxicity from binding additional targets. It has been established that both ligand traps and mAbs have therapeutic relevance. mAbs are being investigated for new uses, and their therapeutic potential has been increased by their recent design, which allows them to target two or more sites at once.
Recent advances in machine learning (ML) and deep learning (DL) have opened up much broader avenues for therapeutic antibody design, with implications for fully computational antibody design. This makes antibody design in the discovery, optimization, and developability evaluation aspects one of AI's main areas of interest in the biological pharmaceutical industry [24]. By utilizing datasets of antibody libraries for both high and low affinity and non-specific binding, machine-learning models can predict antibody affinity and non-specific binding. This enables the co-optimization of therapeutic antibody affinity and specificity, thereby accelerating the development of highly potent antibody drugs.
Rising demand for targeted therapies
The need for targeted medicines is rising significantly in the monoclonal antibodies therapeutics market. The rising incidence of chronic illnesses, including cancer, autoimmune conditions, and infectious infections, is what is driving this need. Because monoclonal antibodies can target specific antigens, they have become a favored therapeutic option, leading to more individualized and effective treatment outcomes. Monoclonal antibody treatments are gaining popularity among patients and healthcare professionals as awareness of their advantages in targeted therapy increases.
High development & manufacturing cost
The high cost of creating and manufacturing monoclonal antibodies is the main obstacle facing the market. The lengthy and complex procedures required to get mAbs, including costly testing and legal compliance, might be prohibitively expensive. The high costs may deter small businesses from joining the market and may restrict patients' access to such sophisticated treatments, thus hindering the expansion of the monoclonal antibody industry.
Growing mAB therapies pipeline
The biopharmaceutical industry is expanding rapidly in this field, as seen by the growing number of monoclonal antibody (mAb) therapeutics being developed as a result of ongoing research and innovation. As the public's perception of mAbs as successful therapies for a variety of ailments, including cancer, autoimmune disorders, and infections, has grown, so too has the number of new mAb products. A steady flow of new medications is brought to market by ongoing clinical trials and research into new targets and treatment modalities, which support the growing monoclonal antibody pipeline.
By type, the human mAB segment led the monoclonal antibodies therapeutics market in 2024. The use of human monoclonal antibody immunotherapy in clinical settings has long been a promising idea, and more and more of these antibodies are progressively becoming accessible. Human monoclonal antibodies are utilized in immunotherapy for autoimmune disorders and a number of blood cancers, including lymphoma and leukemia.
By type, the humanized mAB segment is expected to grow at the fastest rate in the monoclonal antibodies therapeutics market during the forecast period. Humanized monoclonal antibodies are useful treatments for autoimmune illnesses and cancer because they have a number of advantages over conventional medicines, such as decreased immunogenicity, increased effectiveness, and greater target selectivity. By making them more like human antibodies, humanized antibodies reduce the possibility that the body's immune system may mistake them for alien substances and launch an attack. With careful engineering, these antibodies can target certain antigens linked to disease processes, improving treatment outcomes and minimizing side effects.
By application, the cancer segment held the largest share of the monoclonal antibodies therapeutics market in 2024. Immunotherapy based on monoclonal antibodies is becoming more and more recognized as a crucial component of cancer treatment, in addition to surgery, radiation, and chemotherapy. Monoclonal antibodies have a broad variety of therapeutically meaningful mechanisms of activity. Additionally, antibodies can specifically target tumor cells and promote the development of long-lasting immune responses that fight tumors. Because antibodies offer so many advantages as a therapeutic platform, new methods of cancer therapy have been developed that will have a big impact on cancer care.
By application, the autoimmune disease segment is anticipated to achieve the fastest growth rate in the monoclonal antibodies therapeutics market during the forecast period. The market for mAbs has expanded rapidly in recent years. More than 250 therapeutic mAbs are now undergoing clinical trials, and they have grown to be an important component of several pharmaceutical product lines. Over the last three decades, a number of monoclonal antibodies (mAbs) have been introduced to treat a variety of autoimmune illnesses, revolutionizing the treatment of autoimmune diseases. Monoclonal antibodies can decrease the overreactions that define autoimmune disorders by targeting several immune system components.
By distribution channel, the hospital pharmacy segment was dominant in the monoclonal antibodies therapeutics market in 2024. The hospital pharmacy, one of the most crucial departments in hospitals, is responsible for the procurement, storage, compounding, dispensing, manufacturing, testing, packing, and distribution of pharmaceuticals. Hospital pharmacists play a crucial role in providing clinical and pharmacological expertise to patients and medical staff in addition to distributing drugs. The pharmacy department collaborates closely with other medical professionals and provides staff with guidance on how to use pharmaceuticals safely and effectively, including dosage, formulation, administration, and drug monitoring.
By distribution channel, the online pharmacy segment is anticipated to be the fastest growing in the monoclonal antibodies therapeutics market during the forecast period. The ease and accessibility provided by internet platforms have transformed many aspects of healthcare in today's fast-paced, time-sensitive world. These digital platforms have completely transformed the pharmacy experience for customers worldwide, offering unmatched accessibility, convenience, cost savings, and enhanced privacy. Online pharmacies will likely become increasingly important in determining how healthcare is delivered in the future as technology continues to develop, offering innovative ways to meet patients' evolving needs.
North America dominated the monoclonal antibodies therapeutics market in 2024, mostly because of a highly developed healthcare system, more patient awareness, and a bright future for cancer research. This field benefits from significant government funding to further cancer research, which quickly changes the production and accessibility of monoclonal antibodies for therapeutic applications. These significant players in the market, like Pfizer Inc., Amgen, Inc., and Merck & Co., promote a competitive atmosphere that encourages collaboration and creativity. With major businesses continuing to focus on their R&D activities, the North American market is anticipated to maintain its dominant position and see steady expansion over the next years.
The American Cancer Society estimates how many new cases and deaths of cancer occur in the US each year. The United States was expected to see 611,720 cancer-related fatalities and 2,001,140 new cancer cases in 2024. Cancer has affected almost every American, and the majority of American voters want more funding for cancer research. In fiscal year 2024, DCCPS awarded approximately 925 grants totaling around $583 million to support studies aimed at enhancing the quality of life for cancer survivors and reducing cancer risk, incidence, and mortality both domestically and internationally. The division also provided $87 million in contract funding, including the SEER Program.
In Canada, a rare illness claims the lives of 14,000 children under the age of 15 every year. With over 7,000 rare diseases identified, collaboration among researchers nationwide is crucial to enhancing the health outcomes for all children and adolescents with rare conditions. For this reason, in 2024, Health Minister Mark Holland, who is Honourable, stated that the Canadian government will be contributing $20 million over five years.
Asia Pacific is estimated to host the fastest-growing monoclonal antibodies therapeutics market during the forecast period. The market potential is further increased by the region's growing disposable income and a sizable patient base in need of mAb cancer therapies. A favorable environment for the development of mAb is also created by ongoing investments in cutting-edge medical technology and a growing focus on bettering healthcare. Pharmaceutical businesses in nations such as China and India have so huge potential hence are particularly tempting for investments in clinical research. This focus on R&D is projected to fuel the growth of the monoclonal antibodies market in the area considerably.
According to research, 31.5–35.5 million Chinese individuals (2.7–3.0% of the Chinese population) suffer from one of the eight most prevalent autoimmune disorders. These figures are about in line with estimates from Western nations. In China, autoimmune thyroid disorders and RA account for the great bulk of this burden. Over the past ten years, China's need for autoimmune treatment has rapidly increased. Both output and demand will keep increasing over the next ten years.
About 80 million cases of rare illnesses are thought to exist in India, making them a public health problem. This is around a sixth of the worldwide burden. The Delhi High Court issued a series of groundbreaking guidelines that would benefit the Indian rare illness community. The court ordered the Union of Government of India to ensure that patients with rare diseases receive care throughout the nation. The National Fund for Rare Diseases (NFRD) will be established in India with a ₹974 crore budget for the fiscal years 2024–2025 and 2025–2026.
Europe is expected to be significantly growing in the monoclonal antibodies therapeutics market during the forecast period. Academic institutions and European labs collaborate to produce monoclonal antibodies. Europe boasts a sophisticated laboratory infrastructure that is expected to drive market demand to a certain degree. This market is expanding at a faster rate due to the rising prevalence of different health conditions. Use of various approaches and strategies, such as recombinant technologies, to enhance the production of antibodies. The European Monoclonal Antibodies Network (EuroMAbNet) is the first European network of labs associated with academic institutions that are all known globally for producing and using verified antibodies. This monoclonal antibody is used by the researcher as a diagnostic or research tool.
About 30 million individuals are believed to be affected by a rare disease throughout the EU, with an estimated 4 million living in Germany alone. More than 30 rare illness centers have been set up at German university hospitals in recent years to address this. Germany is one of the most innovative countries in the world. Germany benefits from an economy that is strongly committed to research and development, which builds on its great scientific system.
Numerous novel cancer treatments developed in the UK will be tested there, advancing the country's life sciences sector as one of the main engines of economic expansion. Through the use of cutting-edge technology and strategies, new collaborations supported by investments from the public and private sectors will test novel methods for treating cancer and other life-threatening illnesses with quicker diagnosis and better therapies. It coincides with UK Research and Innovation's announcement of a £118 million fund to support the development of innovative health innovations by establishing five new centers from Glasgow to Bristol.
In March 2024, We think more should be done to meet the needs of people living with retinal conditions and to preserve sight, said V Simpson Emmanuel, CEO and managing director of Roche Pharma India, in a statement on the launch. Retinal illnesses are frequently overlooked or discovered late, resulting in vision loss, although cataracts and other frontal eye problems are well-known and actively treated. Our dedication to introducing the best-in-class technologies to India is demonstrated by the launch of Vabysmo, which signifies our debut in the ophthalmology market there. For patients, their caregivers, and healthcare systems, Vabysmo provides a more convenient and efficient treatment plan with fewer eye injections over time, all while preserving and enhancing vision and anatomy.
By Type
By Application
By Distribution Channel
By Region
February 2025
December 2024
August 2024
July 2024